Black Diamond Therapeutics (BDTX) Retained Earnings (2018 - 2021)
Historic Retained Earnings for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q3 2021 value amounting to -$218.0 million.
- Black Diamond Therapeutics' Retained Earnings fell 12798.91% to -$218.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was -$218.0 million, marking a year-over-year decrease of 12798.91%. This contributed to the annual value of -$118.2 million for FY2020, which is 13194.82% down from last year.
- Black Diamond Therapeutics' Retained Earnings amounted to -$218.0 million in Q3 2021, which was down 12798.91% from -$182.9 million recorded in Q2 2021.
- Over the past 5 years, Black Diamond Therapeutics' Retained Earnings peaked at -$15.7 million during Q4 2018, and registered a low of -$218.0 million during Q3 2021.
- In the last 4 years, Black Diamond Therapeutics' Retained Earnings had a median value of -$95.6 million in 2020 and averaged -$107.9 million.
- In the last 5 years, Black Diamond Therapeutics' Retained Earnings plummeted by 22440.17% in 2019 and then crashed by 12798.91% in 2021.
- Quarter analysis of 4 years shows Black Diamond Therapeutics' Retained Earnings stood at -$15.7 million in 2018, then crashed by 224.4% to -$51.0 million in 2019, then plummeted by 131.95% to -$118.2 million in 2020, then plummeted by 84.36% to -$218.0 million in 2021.
- Its Retained Earnings was -$218.0 million in Q3 2021, compared to -$182.9 million in Q2 2021 and -$148.5 million in Q1 2021.